Biosimilar developer Sandoz today announced the launch of its biosimilar adalimumab, Hyrimoz, in Spain. The biosimilar, referencing Humira, was authorized for sale in the European Union in July 2018.
Biosimilar developer Sandoz today announced the launch of its biosimilar adalimumab, Hyrimoz, in Spain. The biosimilar, referencing Humira, was authorized for sale in the European Union in July 2018.
The biosimilar is approved for all of the indications of the reference adalimumab, and is available in 40-mg doses for subcutaneous injection in either a syringe or prefilled pen.
"The debilitating effect that conditions such as rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis have on the individual is having an increasing impact on health systems throughout the world," said Joaquín Rodrigo Poch, general director of Sandoz Iberia, in a statement announcing the biosimilar’s launch. He added that the biosimilar will free up resources that can be directed to patient care and the sustainability of the healthcare system as a whole.
Containing healthcare spending is a major challenge that faces policy makers in all developed countries, and Spain is no exception. In fact, according to a 2017 paper, Spain’s spending on healthcare has long been growing faster than its national income.1 The nation’s aging population, high unemployment that limits the tax revenue that funds the system, and the rise of specialty medicines have put further pressure on the country to improve its system’s sustainability.
Yet according to a 2018 report from Medicines for Europe, pharmaceuticals now comprise 16.7% of total healthcare spending in Spain, and that figure saw a 9% decrease between 2008 and 2011 amid a push to reduce the prices of generic medicines.
The market entry of biosimilar adalimumab could help Spain to reduce its pharmaceutical spending further if the country is able to mirror the successes of its EU counterparts; in November 2018, the United Kingdom announced that adding biosimilar adalimumab to its National Health Service would allow the country to cut its spending on adalimumab by 75%.
While Hyrimoz is also approved in the United States, having earned FDA authorization in October 2018, the drug will not enter the US market before September 2023 per the terms of a patent dispute settlement between Sandoz and Humira maker AbbVie.
Reference
1. Avanzas P, Pascual I, Moris C. The great challenge of the public health system in Spain. J Thorac Dis. 2017;9(suppl 6):S430-S433. doi: 10.21037/jtd.2017.04.59.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.